Syndax Pharmaceuticals (SNDX) Gets a Buy From Stifel Nicolaus
Syndax Pharmaceuticals Analyst Ratings
Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $30
Stifel: Maintaining the Syndax Pharmaceuticals (SNDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $39.00 to $40.00.
Syndax Pharmaceuticals Analyst Ratings
Buy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug Candidate
Analysts' Top Healthcare Picks: Elanco Animal Health (ELAN), Syndax Pharmaceuticals (SNDX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), BioCryst (BCRX) and Syndax Pharmaceuticals (SNDX)
HC Wainwright & Co. : The Syndax Pharmaceuticals (SNDX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $41.00.
Syndax Pharmaceuticals Analyst Ratings
Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)
Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects
Syndax Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)
Syndax Pharmaceuticals Analyst Ratings
Syndax Pharmaceuticals Analyst Ratings
Buy Rating for Syndax Pharmaceuticals Amidst Strategic Progress and Regulatory Milestones
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
No Data